Medical Oncologist
CION Cancer Clinics
Newer combinations being studied in liver cancer | CION Cancer Clinics
Researchers are testing liver cancer medicines in pairs, usually an immunotherapy drug joined with a second immunotherapy drug, a targeted tablet or a liver procedure. Some pairings have beaten today's standard and others have not. This page explains the main directions, how to read a research headline, and who is unlikely to be offered a newer combination. It is written to inform, not to recruit. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What new drug combinations are being tested in liver cancer?
- Which kinds of combinations are researchers studying?
- How does a combination go from a study to normal treatment?
- What do the words in a research headline mean?
- Is a newer combination always better than the standard?
- Who is unlikely to be offered a new combination?
- What this page cannot tell you
- Common questions about newer liver cancer combinations
The short answer
What new drug combinations are being tested in liver cancer?
Researchers are testing medicines in pairs, and sometimes in threes, because one medicine on its own rarely holds liver cancer back for long. Most combinations join an immunotherapy drug with a second immunotherapy drug, with a targeted tablet, or with a liver procedure such as TACE.
This page is about hepatocellular carcinoma (HCC), the cancer that starts in the liver's own cells. If your scan shows cancer that spread to the liver from the bowel, breast or elsewhere, the research is different and follows the original cancer.
Why combinations at all
Liver cancer is clever at escaping a single attack. One medicine may wake the immune system up while another cuts the blood supply the tumour needs. Together they can sometimes do what neither does alone. Sometimes they simply add side effects without adding benefit, which is exactly why they are tested carefully first.
A combination is already standard for many people. The pairing in atezolizumab plus bevacizumab started as a research question and is now often the first choice. The combinations on this page are the next questions.
This page explains the research. It is not an invitation to join any study.Four directions
Which kinds of combinations are researchers studying?
Almost every liver cancer study running today fits into one of these four groups.
Two immunotherapy drugs together
One drug releases one brake on the immune system and a second drug releases a different brake. Durvalumab with tremelimumab, and nivolumab with ipilimumab, are examples. The cost is more immune side effects, such as inflammation of the liver, bowel or skin.
Immunotherapy with a targeted tablet
An immunotherapy drug is paired with a tablet such as lenvatinib or cabozantinib, which slows the blood vessels feeding the tumour. Some of these pairings beat the standard in studies. Others did not, which is an honest and useful answer too.
Medicines with a liver procedure
Immunotherapy or a tablet is added to TACE or Y-90, the treatments that deliver chemotherapy or radiation straight into the tumour's artery. The idea is that the procedure exposes the cancer and the medicine finishes the job.
More on this in immunotherapy combined with TACE or Y-90.Medicines around surgery
Studies give immunotherapy before an operation to shrink the tumour, or after surgery or ablation to lower the chance of the cancer coming back. Early results have been mixed, and this is still a research question rather than routine care.
Not sure whether this applies to you?
Ask an oncologistFrom idea to routine
How does a combination go from a study to normal treatment?
Early safety studies
A small group of people receive the pair to learn whether the two drugs can be given together safely and what the side effects look like. Nobody yet knows whether it works better.
Larger studies of effect
More people are treated to see whether tumours shrink or stop growing. A promising signal here still fails later surprisingly often.
The comparison that counts
The new pair is tested head to head against today's standard, with people placed in each group by chance. Only this kind of study can show that a combination is genuinely better. The trial phases page explains these stages in more detail.
Approval, then availability
Regulators in each country decide separately. A pair approved in the United States, Europe or China may not yet be approved or sold in India, and the price can put it out of reach even when it is.
Reading the news
What do the words in a research headline mean?
- Randomised
- People were placed in the new or the standard group by chance. This is the fairest way to compare two treatments.
- Response rate
- How many tumours shrank on scans. Shrinking is encouraging but does not always mean people live longer or better.
- Overall survival
- Whether people in the new group lived longer than those in the standard group. This is the result that matters most.
- Did not meet its endpoint
- The study did not prove the new pair was better than the standard. It is not a scandal. It is the system working.
- CTRI
- The Clinical Trials Registry of India, where every trial run in India must be listed before it starts.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
Is a newer combination always better than the standard?
"Two medicines must be stronger than one."
Sometimes they are. Sometimes the second medicine adds side effects and nothing else. Several promising pairs in liver cancer did no better than the standard when they were properly compared.
"If it is in the news, my father should be on it."
News reports often describe early studies with small numbers of people. A result that excites researchers may be years away from being a proven choice, and may never become one.
"Trial treatment is a last resort for people with no hope."
Many liver cancer studies are for people starting treatment, or for people who have just had surgery. Taking part is a choice at many points, not a sign that the doctors have given up.
"Asking about research will offend our doctor."
A good oncologist expects the question. It is a fair thing to ask, and the answer helps you understand why the doctor is recommending what they recommend.
Who this does not suit
Who is unlikely to be offered a new combination?
Most combinations are tested in people whose liver still works well, usually described as Child-Pugh A. If cirrhosis is advanced, with jaundice, fluid in the abdomen or confusion, the liver may not cope with two strong medicines, and studies usually do not accept these patients. Comfort and liver care come first for them.
Other groups who are usually left out
- People who have had a liver transplant, because immunotherapy can trigger rejection. See why it is avoided.
- People with an active autoimmune illness, which immunotherapy can make worse.
- People with large untreated varices, if the pair includes a drug that raises bleeding risk.
- People with a small cancer that can be removed or ablated now. For them a proven, curative treatment should not wait for a study.
Hepatitis B does not rule anyone out by itself, but it must be controlled with antiviral tablets before immunotherapy starts.
Being straight with you
What this page cannot tell you
It cannot tell you which combination, if any, is right for you. That depends on the size and spread of the tumour, how well the liver is working, your general fitness and what you have already had. Only a team that has seen your scans and blood reports can weigh those together.
It cannot tell you what is open in India today
Studies open and close all the time. What is available in Hyderabad this year may not be next year. Your oncologist can look at the Clinical Trials Registry of India with you, and our page on finding trials in India explains how to search it yourself.
It cannot promise a result
The evidence on most of these pairs is still being gathered, and some of it is thin. At CION, the tumour board reviews every case and can explain where the standard ends and research begins for your situation. A second opinion is a reasonable step if you are unsure.
Questions we are asked
Common questions about newer liver cancer combinations
Is atezolizumab plus bevacizumab still new?
No. It began as a research combination and is now one of the usual first choices for advanced liver cancer when the liver is working well. It is available in India. Newer pairings are usually compared against it, so it remains the yardstick other combinations have to beat.
Are these new combinations available in India?
Some are, some are not, and some are only given inside a trial or through import. Approval in another country does not mean approval here. Ask your oncologist plainly whether a combination you have read about is approved in India and whether it is actually stocked.
Can I ask for a combination that is still in research?
You can ask, and you should get an honest answer. Outside a trial, an unproven pair is usually not recommended, because nobody yet knows whether the extra side effects are worth it. Your oncologist can explain what the evidence shows and whether any study could suit you.
Do combinations have more side effects?
Usually yes. Two medicines working in different ways can each bring their own side effects, and immune side effects can affect the liver itself. The details for each drug are on the immunotherapy for liver cancer page. Report new symptoms early.
Does joining a study mean I might get a dummy medicine?
In cancer studies, the comparison group almost always gets the current standard treatment, not nothing. A dummy tablet is sometimes added on top so nobody knows which group they are in. You should be told exactly what each group receives before you agree to anything.
Are the combinations for bile duct cancer the same?
No. Bile duct cancer is a different disease with its own research. Its tumours should have DNA testing, called molecular profiling, because some have targeted options. That testing does not promise a treatment, but it can open choices that would otherwise be missed.
Who pays for treatment inside a trial?
It varies. The study sponsor often pays for the study medicine and some tests, while other costs may still fall on the family. Ask for this in writing before you agree. Our page on who pays in a trial lists the questions to ask.
Who can help me make sense of what I have read?
Your oncologist is the right person, ideally with your scans and reports in front of them. If you would like a second view, call the CION helpline. The tumour board can review the case and explain which options are proven, which are still research, and which fit your liver.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — What's New in Liver Cancer Research?
- Cancer Research UK — Research and clinical trials for liver cancer
- American Cancer Society — Immunotherapy for Liver Cancer
- Clinical Trials Registry - India — Clinical Trials Registry - India
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
How to find liver cancer trials in IndiaSearch the registry yourself, step by stepShould I join a liver cancer trial?Weigh the benefits and the trade-offs honestlyAtezolizumab plus bevacizumabThe standard most new pairs are compared againstImmunotherapy combined with TACE or Y-90Where medicines meet liver procedures
Talk to us
Read about a new combination and wondering if it applies to you?
Send us the scans and reports, and the tumour board can explain which options are proven and which are still research for your liver. One helpline serves every CION centre.